Philip Morris Prepares for Q2 Earnings Amidst Positive Momentum

Jul.17.2023
Tobacco giant Philip Morris is expected to report strong earnings fueled by IQOS and ZYN, despite margin challenges.

Shares of tobacco giant Philip Morris International Inc. (NYSE: PM) continued to show positive momentum on Wednesday, with the stock gaining 6% over the past month. Investors eagerly await the company's second quarter 2023 earnings report, which is scheduled to be released on Thursday, July 20, before the market opens. 

 

Revenue Expectations

Analysts are projecting that Philip Morris will report revenue of $8.6 billion for the second quarter of 2023. This estimate suggests a growth of 10% compared to the same period last year. In the first quarter of this year, the company's revenue saw a 3.5% year-over-year increase, reaching $8 billion. 

 

Earnings Forecast

Philip Morris has provided guidance for adjusted earnings per share (EPS) ranging from $1.42 to $1.47 for the second quarter of 2023. Analysts, on the other hand, estimate EPS of $1.47, which is higher than the $1.32 reported in the same quarter last year. The first quarter of 2023 saw a 4.4% decrease in adjusted EPS, amounting to $1.38. 

 

Strength in IQOS

Philip Morris is expected to benefit from the continued strength of its IQOS product, which has been gaining market share across various regions and showing a rise in adoption. The company noted in its first quarter report that as of March 31, there were approximately 25.8 million IQOS users. Furthermore, with the introduction of the IQOS ILUMA, the product category has experienced further growth, attracting an estimated 10 million users. ILUMA has dominated market volumes in countries like Japan, Switzerland, and Spain, accounting for over 85% of HTU (heated tobacco unit) volumes. Alongside promising growth in developed countries, PMI is witnessing encouraging expansion for IQOS in low and middle-income markets. 

 

Growth of ZYN

Philip Morris will also benefit from the growth of nicotine pouch brand ZYN, which it acquired through the Swedish Match acquisition. In the first quarter, ZYN witnessed a 47% increase in volume in the US. The company sees significant potential to expand distribution and velocity, referring to the number of ZYN cans sold per store per week. 

 

Margin Challenges

In the first quarter, Philip Morris faced challenges with its margins due to inflationary pressures and supply chain obstacles. These pressures are expected to persist through the year, impacting the company's margins. Despite this, Philip Morris continues to make growth investments to support its business expansion. 

 

Investors are eager to see the financial results of Philip Morris International Inc. as the company prepares to release its second quarter 2023 earnings report. With expectations of revenue growth and increased earnings per share, fueled by the robust performance of IQOS and the potential of ZYN, Philip Morris appears to be well-positioned to meet market expectations. However, challenges with margins and inflationary pressures remain an ongoing concern.


Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Trump Picks White House Health Policy Aide Heidi Overton to Lead FDA, Pending Senate Confirmation
Trump Picks White House Health Policy Aide Heidi Overton to Lead FDA, Pending Senate Confirmation
U.S. President Donald Trump has chosen White House health policy aide Heidi Overton to lead the Food and Drug Administration, Bloomberg reported, citing a person familiar with the matter. Overton currently works on health policy at the White House and previously held a senior role at the America First Policy Institute. If confirmed by the Senate, she would take over an FDA that has experienced months of senior-level turnover. The agency regulates products representing roughly one-fifth of U.S. consumer spending, including e-cigarettes, drugs, vaccines and much of the food supply.
News
Aug.19
BAT's VELO Partners With McLaren F1 Team for Global Fan Campaign to Expand Nicotine Pouch Brand Reach
BAT's VELO Partners With McLaren F1 Team for Global Fan Campaign to Expand Nicotine Pouch Brand Reach
BAT-owned nicotine pouch brand VELO and the McLaren Mastercard Formula 1 Team have launched a global fan engagement campaign offering motorsport enthusiasts opportunities to win exclusive team-related experiences. The initiative aims to connect racing culture, fan interaction and VELO’s brand experience across global markets. The partnership reflects BAT’s broader strategy of expanding modern nicotine product brands beyond traditional tobacco categories through lifestyle and cultural marketing.
Jul.23
Indiana’s Foreign-Made Vape Ban Takes Effect, Forcing Brands and Retailers to Adjust Supply Chains
Indiana’s Foreign-Made Vape Ban Takes Effect, Forcing Brands and Retailers to Adjust Supply Chains
A new Indiana law restricting the sale of foreign-made vape products has taken effect, requiring retailers to adjust inventory and sourcing practices. According to The Sun, WDRB and other reports, some local vape shops are reviewing product origins and supplier information to comply with the new requirements. The measure represents a broader shift in U.S. vape regulation, with oversight expanding beyond product authorization and sales rules toward manufacturing origin and supply-chain management.
Jul.24
Shopify Requires Merchants to Remove All Vape Products by July 8, Reshaping Online Sales Channels
Shopify Requires Merchants to Remove All Vape Products by July 8, Reshaping Online Sales Channels
Shopify has instructed merchants using its web-hosting services to remove vape products from their online stores by July 8, 2026. The policy expands beyond illegal products and applies to all electronic nicotine delivery systems (ENDS), marking a broader shift in online platform oversight of nicotine sales.
Innovation
Jul.14 by 2Firsts Perspectives
JTI Makes Third Bet on South Korea as Ploom AURA Enters a Market Dominated by lil and IQOS
JTI Makes Third Bet on South Korea as Ploom AURA Enters a Market Dominated by lil and IQOS
Japan Tobacco International is stepping up its heated tobacco push in South Korea with Ploom AURA. Since its official launch in April 2026, the device's limited First Edition and Glacier White version have sold out, while distribution has expanded across Seoul, Incheon, Gyeonggi Province and airport duty-free channels. The rollout marks JTI's third major attempt to build a stronger heated tobacco position in South Korea, following Ploom TECH in 2019 and Ploom X Advanced in 2024. At the group level, JT plans to invest about ¥800 billion, approximately $5 billion, in reduced-risk products from 2026 through 2028, with heated products and Ploom identified as its primary investment priority.
Aug.14
Korean component maker ITM Semiconductor says Indonesia unit starts e-cigarette device output as related Q1 revenue rises 55.4%
Korean component maker ITM Semiconductor says Indonesia unit starts e-cigarette device output as related Q1 revenue rises 55.4%
South Korea’s KOSDAQ-listed electronics-component maker ITM Semiconductor said its Indonesia subsidiary has begun full-scale mass production of e-cigarette devices, with first-quarter revenue from the business rising 55.4% year on year to 42.1 billion won, Maeil Business Newspaper reported.
Jul.08